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ABSTRACT
Since the 19th century, neuroendocrine neoplasms (NEN) have been 
identified. Right up to the present day, the nomenclature is still under debate 
reflecting the heterogeneity of these tumors. Although some of them are slow 
growing, some can be fearfully aggressive and may develop in almost any 
organ of the abdomen, thorax, neck, skin, and gonads. The most commonly 
observed sites of NEN are the lung and the gastroenteropancreatic system 
(GEP), where more than 50 entities have been observed. In case of a NEN 
of unknown primary tumor, the histopathological diagnostic workup includes 
immunohistochemistry for chromogranin A and synaptophysin, followed by 
specific tissue markers. Clinical presentation is very diverse, depending on 
the primary site and functionality of the tumor. In the case of the GEP-NEN, 
the main symptoms are abdominal pain, diarrhea, weight loss, gastrointestinal 
bleeding, or bowel obstruction. The presence of neuropsychiatric symptoms 
is not insignificant in this group of tumors. The authors report a case of a 
51-year-old man who sought medical attention because of a three-month 
history of a consumptive disease. The diagnostic workup disclosed a diffuse 
nodular infiltration of the lungs, hypokalemia, and hypercalcemia in a cachectic 
patient. The clinical investigation could not proceed because of an infectious 
intercurrence, which led to the fatal outcome. Autopsy findings showed a 
diffuse metastatic NEN. The primary tumoral site could not be demonstrated 
with the available immunohistochemical panel.
Keywords: Neuroendocrine tumor; Neoplasms, unknown primary; Neoplasms, metastasis; 
Diarrhea; Cachexia.
CASE REPORT
A 51-year-old male patient sought medical 
attention complaining of pain for the past three 
months in the lower abdomen radiating to the right 
groin and inferior limb. More recently he referred 
watery diarrhea with up to three evacuations per day 
without blood or mucus accompanied by anorexia 
and weight loss of 20 kg during this period. Since 
the onset of the symptoms, he has been presenting 
depression. His medical history included the 
diagnosis of epilepsy, alcohol consumption for seven 
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parenteral hydration associated with furosemide 
and pamidronate. After 13 days of hospitalization, 
he developed signs of septicemia. He died without 
diagnosis of the underlying disease. An autopsy 
was performed.
AUTOPSY FINDINGS
On external examination, the anthropometric 
measures revealed the body of a man 176 cm in 
height, which weighed 47 kg (Body Mass Index = 15). 
The pancreas weighed 170 g (RV = 103-186 g) and 
showed multiple grayish nodules, with up to 0.5 cm 
in diameter (Figure 2).
On light microscopy, there was a trabecular 
proliferation of cells with mild atypia displaying 
“salt and pepper chromatin” (Figure 3). The 
immunohistochemical panel revealed positivity 
for chromogranin, synaptophysin, cytokeratin 
years in his youth, and smoking for a long period 
right up to the date of admission. On admission, the 
physical examination showed an emaciated patient, 
but ruddy, hydrated, acyanotic, and anicteric. Vital 
signs were within normal limits. Examination of 
the lungs, heart, abdomen, and lower limbs was 
unremarkable. The admission laboratory tests are 
presented in Table 1.
The endoscopic examination of the upper 
gastrointestinal tract and colon were normal. The 
chest x-ray (Figure 1) showed the presence of tiny 
nodules, diffusely distributed throughout both lungs.
During hospitalization, the patient developed 
worsening of the depression symptoms followed 
by an altered level of consciousness and attention 
deficit. He started presenting with a cough and 
respiratory distress. When rales were detected on 
the lungs, vancomycin and imipenem were started. 
Because of the elevated serum calcium levels 
he was treated throughout hospitalization with 
Table 1 – Laboratory diagnostic work up at admission
Exam Result RV Exam Result RV
Hemoglobin 13.7 g/dL 13.0-18.0 g/dL Creatinine 0.58 mg/dL 0.7-1.0 mg/dL
Hematocrit 35.5% 40.0-52.0% BUN 23 mg/dL 10-50 mg/dL
Leukocytes 9.16.10³/mm3 4.0-11.10³/mm3 Calcium 12.5 mg/dL 8.60-10.20 mg/dL
Neutrophils 68.2% 46-75% PTH <3 pg/mL 16-87 pg/mL
Eosinophils 0.9% 1-4% K+ 2.1 mEq/L 3.5-5.0 mEq/L
Basophils 0.5% 0-2.5% Na+ 132 mEq/L 135-145 mEq/L
Lymphocytes 22.0% 18-40% Glucose 154 mEq/L 70-99 mEq/L
Monocyte 8.4% 2-9% AST 22 U/L <37 U/L
Platelets 356.10³/mm3 140-450.10³/mm3 ALT 26 U/L <41 U/L
ALT = alanine transaminase; AST = aspartate transaminase; BUN = blood urea nitrogen; Na+ = sodium; K+ = potassium; PTH = parathyroid 
hormone; RV = reference value.
Figure 1 – Chest radiography showing diffuse 
bilateral nodules.
Figure 2 – Gross examination of the pancreas 
showing multiple grayish nodules measuring up to 
0.5 cm in diameter spread throughout the organ.
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The right and left lungs weighed 670 
(RV = 360-570 g) and 534 g (RV = 325-480 g), 
respectively. Both lungs exhibited a gray and 
smooth external surface, with anthracotic deposits. 
The pleural surface showed multiple grayish 
nodules (Figure 5). On sectioning, the parenchyma 
was aerated and exhibited a spongy consistency. 
Reddish areas of consolidation were detected 
in both inferior lobes. No pleural effusion was 
detected. On histological examination, the grayish 
nodules corresponded to neuroendocrine tumors 
in the pleura as well as within the alveolar spaces, 
besides multiple areas of exudative pneumonia 
(Figure 6).
The microscopic examination of the spleen 
showed reactive splenitis. The heart weighted 354 g 
(RV = 270-360 g) and also showed multiple grayish 
nodules throughout the pericardial surface and 
within the myocardium (Figure 7).
The liver weight was normal and also 
presented multiple nodules in the parenchyma 
(Figure 8). The adrenals weighted 10 g each 
(RV = 9.7 each) and showed a yellowish cut 
surface with multiple grayish well-defined nodules 
35BH11, and focal positivity for glucagon and 
somatostatin (Figure 4). The immunohistochemistry 
for insulin, pancreatic polypeptide, and the specific 
transcription factor markers TTF-1 and CDX-2 were 
negative. The tumor cell proliferation, assessed 
by Ki67 antigen, was estimated at 3-20%, which 
corresponds to the well-differentiated grade 2 of the 
WHO classification.
Figure 3 – Photomicrography of the pancreas 
showing trabecular proliferation of cells with mild 
atypia displaying “salt and pepper chromatin” 
(H&E, 400x).
Figure 4 – Photomicrography of the pancreatic tumoral nodule. The immunohistochemical panel revealed 
positivity for chromogranin (A), synaptophysin (B), and focal positivity for glucagon (C) and somatostatin (D) 
(100x).
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The histological examination revealed 
a lipoma with a neuroendocrine nodule within 
the adipose tissue, with the same histological 
characteristics of the tumor cited above. The clinical 
data added to the autopsy findings concluded that 
sepsis and pneumonia were the immediate cause 
of death.
DISCUSSION
The neuroendocrine system, a fascinating 
chapter of histology, is represented by scattered 
cells throughout the body identifiable by their 
reactivity for chromium and silver salts. Named 
as enterochromaffin cells, argentaffin cells, clear 
cells, enteroendocrine cells, and Kultschitsky cells 
by several investigators, they may give rise to the 
neuroendocrine neoplasm (NEN). In the 19th century, 
Langhans (1867), Lubarsch (1888), and Ransom 
(1890) described tumors exhibiting neuroendocrine 
characteristics.1 In 1907, Siegfried Oberndorfer 
coined the term karzinoide (“carcinoma-like” in 
German), to describe the feature of behaving like a 
benign tumor despite the microscopically malignant 
appearance.1 Even till now, the nomenclature is 
still under debate reflecting the heterogeneity of 
these tumors.2 Although the tumors are often slow 
growing, compared with adenocarcinomas, they 
can also be extremely aggressive.3
The incidence of NENs ranges from 2.5 to 5 
cases per 100,000 in the Caucasian population.4 This 
has substantially increased over recent decades, 
partially due to improved diagnostic techniques and 
clinical awareness.5-8
Figure 5 – Right pleural surface showing multiple 
grayish nodules.
Figure 6 – Photomicrography of the lung showing 
areas of intra-alveolar exudative pneumonia 
(HE, 400x).
Figure 7 – Gross examination of the heart showing multiple grayish nodules throughout the pericardial 
surface and within the myocardium.
(Figure 9). As well as the pancreas, the lungs, 
heart, liver, adrenals, thyroid, prostate, kidneys, and 
bone marrow showed microscopic neuroendocrine 
tumors on light microscopy. In the dorsum, the 
patient had a subcutaneous well-defined nodule, 
measuring 5.0 cm in its longest axis, which had a 
yellowish and homogeneous cut surface.
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NEN (10%), insulinomas (8%), and gastrinomas 
(4%) were the most common. Glucagonoma, 
VIPoma, and somatostatinoma totaled less than 
2%. In this study, 44% of patients presented with 
widespread disease at the time of diagnosis, which 
is different from the North American series where 
12.9% of patients showed this stage at the time 
of diagnosis.12 The patient reported in this case 
study presented a widespread and advanced-stage 
disease, evidenced by the necropsy findings and 
clinically by the cachexia that became symptomatic 
three months before medical attention.
Neuroendocrine carcinoma of unknown 
primary (NCUP) accounts for 9-13% of all NEN, and 
5% of all malignant neoplasm.4,5,13 These tumors 
arise from an occult or clinically undetectable primary 
site, which can be located in the liver, bronchus, 
pancreas, colon, rectum, or elsewhere. Two 
different clinicopathologic subsets of these tumors 
have been described. The first subset includes 
low-grade neuroendocrine carcinomas (metastatic 
well-differentiated NEN) usually involving the liver 
or presenting with symptoms due to the secretion of 
vasoactive peptides (functional tumors). This subset 
of tumors presents an indolent behavior. The second 
subset includes high-grade poorly differentiated 
carcinomas, which present rapidly growing 
biological behavior.2 It cannot be identified if these 
tumors arise from an occult primary gastrointestinal 
or pulmonary site or even from multipotent stem 
cells.13 The tumor presented in this case study 
belongs to the first group, with a proliferation cell 
index classified as G2. Unfortunately, the available 
immunohistochemical panel could not precisely 
elucidate the primary tumor, but in accordance with 
the available results and the literature data the tumor 
most probably belongs to the GEP-NEN group.
The WHO classification of 2010 presumes 
that all NEN are potentially malignant, but differs 
markedly in respect of their likelihood to develop 
metastases. The classification takes into account 
the tumor proliferative activity measured by 
immunostaining for the cell cycle-dependent marker 
Ki67 antigen, and/or by number of mitoses per unit 
area of tumor (usually expressed as mitoses per 10 
high-power microscopic fields or 2 mm2).14 Therefore 
the tumor is distinguished between well-differentiated 
and poorly differentiated neoplasms.15-17 All well-
differentiated neoplasms, graded G1 (Ki67 < 2%) 
and G2 (Ki67 2-20%), regardless of their biological 
behavior, will be called neuroendocrine tumors 
(NETs). All poorly differentiated neoplasms, graded 
G3 (Ki67 > 20%), will be termed neuroendocrine 
NENs seem to be homogeneous in terms 
of morphology, but depending on their localization, 
these neoplasms reveal distinct phenotypes with 
respect to pathology, immunohistochemistry, and 
hormonal syndromes.9 They may develop in almost 
any organ of the abdomen, thorax, neck, and skin. 
The most commonly observed sites of NEN are 
the lungs and the gastroenteropancreatic system 
(GEP), where more than 50 entities have been 
observed.10 There are rare sites of occurrence, 
which include the larynx, thymus, thyroid, adrenal, 
gonads, kidney.11,12 The incidence of primary site 
may vary with gender and race.5 In the National 
Cancer Institute (USA) survey, from 1950 until 
1999, 13,715 cases were retrieved. The incidence 
of gastrointestinal (GI) NEN was 67.5% and 
bronchopulmonary 25.3%. Within the GI-NEN 
41.8% were localized in the small intestine, 27.4% 
in the rectum, and 8.7% in the stomach.12 A cohort 
study conducted in southern Spain4 comprised 
837 patients and 907 GEP-NET tumors. In this 
study, gastrointestinal sites represented 55% of 
cases followed by nonfunctional pancreatic tumors 
(20%). Among the functional tumors, the enteric 
Figure 8 – Gross examination of the liver presenting 
nodules in the parenchyma.
Figure 9 – Gross examination of the right adrenal 
gland, showing a yellowish cut surface with multiple 
grayish well-defined nodules.
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reported here, the immunostaining was negative for 
both CDX-2 and TTF-1.
A primary neuroendocrine tumor originating 
from the skin (Merkel cell carcinoma) is unlikely since 
the tumor cells were small and well differentiated.
The clinical picture of NEN depends on its 
primary tumor, the presence of metastases, and 
the production of hormones or peptide of clinical 
significance. Among the latter are the insulinoma, 
glucagonoma, gastrinoma, somatostatinoma, 
VIPoma, thymic producing ACTH tumors, and 
others.
In a series of 241 patients with the diagnosis 
of GEP-NEN, the most common symptoms were 
abdominal pain (29.5%), diarrhea (8.7%), weight 
loss (7.5%), gastrointestinal bleeding (5.4%), 
flushing (3.7%), and bowel obstruction (3.3%). In 
this series, neurological and psychiatric symptoms 
were reported in 2.1% of patients, among whom 
9.1% presented pancreatic NENs. Diarrhea can 
be the manifestation of the carcinoid syndrome, 
which is most prevalent in the GEP-NEN and 
some tumors of the bronchopulmonary origin. The 
syndrome becomes evident when metastases are 
present. The diarrhea in these cases occurs due 
to the overproduction of serotonin by the tumor, 
which is responsible for the bowel hypermotility and 
intestinal mucosa hypersecretion. The patient of this 
case study featured a history with few clinical data, 
but abdominal pain, diarrhea, weight loss, and a 
depressed mood were present. The diarrhea could 
be part of a carcinoid syndrome, even in the absence 
of the other carcinoid syndrome symptoms. Diarrhea 
can also be observed in glucagonoma, but is often 
associated with diabetes mellitus and the presence 
of necrolytic migratory erythema (involving the face, 
perineum, or extremities), which were lacking in this 
case. The somatostatinoma also present diarrhea, 
but diabetes mellitus, again, was also present. The 
VIPoma that present clinically with watery diarrhea 
associated with hypokalemia, hypercalcemia, and 
eventually hyperglycemia could be a likely diagnosis 
for this case once the electrolytic disturbances 
were present. Tumors producing calcitonin are not 
usually associated with hypercalcemia, unless bone 
metastases are present.
The laboratory diagnostic workup in 
functional NEN may include the hormonal dosages 
(gastrin, insulin, peptide C, somatostatin, pancreatic 
polypeptide, glucagon, ACTH, cortisol, VIP and 
urinary 5-hydroxy-indol-acetic acid (5HIAA), 
carcinomas (NECs).17,18 The WHO classification 
for lung and thymus NETs relies only on the mitotic 
rate,19 whereas the European Neuroendocrine 
Tumor Society (ENETS) as well as the WHO 
recommend either mitotic rate or Ki67 labeling index 
for gastroenteropancreatic NETs.20
The NEN histopathological workup 
includes the use of the neurosecretory markers, 
chromogranin A (CgA) and synaptophysin. CgA is 
part of the membrane of neurosecretory hormone 
granules, and its positivity depends on the number 
of these intracellular granules being evident in the 
well-differentiated tumors while mild reactions are 
observed in the poor-differentiated, due to the scarcity 
of granules in these tumor cells. CgA may even lack 
in NEN of the lung and rectum. Synaptophysin, on 
the other hand, can be demonstrated in all NEN, 
independently of the number of neurosecretory 
vesicles.10
The search for hormones, biogenic amines, 
and transcription factors is useful in identifying 
the primary tumor in the case of metastases of 
unknown origin. In this setting among the GEP 
system, the vesicular monoamine transporter 2 
(VMTA2) is a marker for enterochromaffin-like 
cells of the stomach. It can be positive also in 
the adrenal medulla and paraganglia cells. NEN 
in the duodenum commonly produces gastrin 
and somatostatin. Serotonin-forming NEN is 
predominant in the ileum and appendix. Pancreatic 
NEN primarily produces insulin, glucagon, 
pancreatic polypeptide, and somatostatin, as 
well as calcitonin, adrenocorticotropic hormone 
(ACTH) or vasoactive intestinal polypeptide (VIP). 
VIP can also be found in adrenal NEN, such as 
pheochromocytoma. These peptide hormones may 
be revealed by immunohistochemistry; however, 
these positive reactions are not necessarily 
correlated with endocrine syndromes.21,22 The 
immunohistochemical research of this case allowed 
the diagnosis of a NEN through the positivity to CgA 
and synaptophysin. The focal positivity to glucagon 
and somatostatin enabled the localization of the 
tumor as being identified from the GEP system. 
Although classified as well differentiated, the 
grade 2 NETs may fail to express strong positive 
immunohistochemical reactions for specific markers. 
The evidence of specific transcription factors is also 
noteworthy for the determination of the primary 
GEP-NEN. In this context, CDX-2 is positive in 90% 
of NEN in the ileum and appendix; Islet-1 is highly 
specific for pancreas; TTF-1 is expressed in about 
50% of bronchopulmonary NEN.10,22 In the case 
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depending on the functional status of the tumor, 
clinical symptoms, and histological features.23 
Even with respect to the diagnosis, the computed 
tomography scan of the chest, abdomen, and 
pelvis complemented by somatostatin receptor 
scintigraphy (SRS) are indicated. Over 90% 
of gastroenteropancreatic NENs, including 
nonfunctioning islet cell tumors and carcinoids, 
have high concentrations of somatostatin receptors, 
and can be imaged using octreotide, a radiolabeled 
form of the somatostatin analog. SRS has also 
been used to help provide information regarding the 
primary tumor location. The endoscopic examination 
is fundamental for the diagnosis of NEN, which is 
included for the determination of the primary tumor 
in case of liver metastasis.23-25 Unfortunately, in this 
case study, this investigation was not undertaken 
because of the lack of clinical suspicion of NEN and 
the short period of hospitalization.
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